Erlotinib-associated interstitial pneumonitis with successful readministration.

Songphol Tungjitviboonkun Naharuthai BumrungratanayosJedsadakorn Jitwimungsanon

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

We assumed that the mechanism for interstitial pneumonitis are diverse and some mechanism is not related with drug directly but rather transient condition and the drug can be readministrated without developing second adverse event. This could lead to change in practice of erlotinib readministration in the future.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
adverse drug
healthcare
primary care
drug induced
current status
quality improvement
tyrosine kinase